Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate

Author: Benzinga Newsdesk | May 07, 2024 04:40pm
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.534 million which missed the analyst consensus estimate of $31.284 million by 5.59 percent. This is a 13.29 percent increase over sales of $26.070 million the same period last year.

Posted In: RIGL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist